Lenalidomide, melphalan, and prednisone followed by lenalidomide maintenance improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F12%3AA13017JD" target="_blank" >RIV/61988987:17110/12:A13017JD - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Lenalidomide, melphalan, and prednisone followed by lenalidomide maintenance improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial

Popis výsledku v původním jazyce

The MM-015 trial assessed lenalidomide-based therapy on health-related quality of life. Patients completed health-related quality of life questionnaires at baseline, after every third treatment cycle, and treatment end. Health-related quality of life improved in all treatment groups during induction therapy. More patients receiving lenalidomide maintenance achieved minimally important differences (P&lt;0.05 for Physical Functioning). Therefore, lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance improves health-related quality of life in patients with newly diagnosed multiple myeloma.

Název v anglickém jazyce

Lenalidomide, melphalan, and prednisone followed by lenalidomide maintenance improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial

Popis výsledku anglicky

The MM-015 trial assessed lenalidomide-based therapy on health-related quality of life. Patients completed health-related quality of life questionnaires at baseline, after every third treatment cycle, and treatment end. Health-related quality of life improved in all treatment groups during induction therapy. More patients receiving lenalidomide maintenance achieved minimally important differences (P&lt;0.05 for Physical Functioning). Therefore, lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance improves health-related quality of life in patients with newly diagnosed multiple myeloma.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2013

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Haematologica

ISSN

1592-8721

e-ISSN

—

Svazek periodika

97

Číslo periodika v rámci svazku

Dec 14

Stát vydavatele periodika

IT - Italská republika

Počet stran výsledku

37

Strana od-do

1-37

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—